- Globus Medical's (GMED) Q3 numbers come in slightly ahead of the Street's expectations.
- U.S. sales growth for the period was 12.6%, while international growth was 19.1%.
- Net income rises 23% Y/Y to $20.3M.
- FY13 outlook: $0.83-0.85/share (versus previous guidance of $0.81/share) on revenue of ~$432M. Consensus is $0.83/share on sales of $432.3M. (PR)